MA46690A - Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 - Google Patents
Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2Info
- Publication number
- MA46690A MA46690A MA046690A MA46690A MA46690A MA 46690 A MA46690 A MA 46690A MA 046690 A MA046690 A MA 046690A MA 46690 A MA46690 A MA 46690A MA 46690 A MA46690 A MA 46690A
- Authority
- MA
- Morocco
- Prior art keywords
- triazolo
- pyrimidine compounds
- pde2 inhibitors
- pde2
- inhibitors
- Prior art date
Links
- 229940121828 Phosphodiesterase 2 inhibitor Drugs 0.000 title 1
- SRNKZYRMFBGSGE-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CN=C21 SRNKZYRMFBGSGE-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196936 | 2016-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46690A true MA46690A (fr) | 2019-09-11 |
Family
ID=57223577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046690A MA46690A (fr) | 2016-11-02 | 2017-10-31 | Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11319321B2 (fr) |
| EP (1) | EP3535268B1 (fr) |
| JP (1) | JP7018944B2 (fr) |
| KR (1) | KR20190067788A (fr) |
| CN (1) | CN109890824B (fr) |
| AU (1) | AU2017353313C1 (fr) |
| BR (1) | BR112019008604A2 (fr) |
| CA (1) | CA3038913A1 (fr) |
| EA (1) | EA039847B1 (fr) |
| ES (1) | ES2912264T3 (fr) |
| MA (1) | MA46690A (fr) |
| MX (1) | MX390505B (fr) |
| WO (1) | WO2018083101A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2765738T3 (es) | 2015-11-02 | 2020-06-10 | Janssen Pharmaceutica Nv | Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo |
| MX385576B (es) | 2016-11-02 | 2025-03-18 | Janssen Pharmaceutica Nv | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2 |
| AU2017353313C1 (en) | 2016-11-02 | 2022-06-09 | Janssen Pharmaceutica Nv | (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors |
| CA3038916A1 (fr) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | Composes de [1,2,4]triazolo[1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 |
| WO2018154133A1 (fr) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga |
| CN115960101B (zh) * | 2022-12-30 | 2024-10-18 | 海南大学 | 7-氧代-4,5,6,7-四氢吡唑并吡啶酰胺类化合物及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU676993B2 (en) | 1991-06-27 | 1997-04-10 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| TR200002182T2 (tr) | 1998-01-27 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | İkame edilmiş aksozaherosayklil faktör xa inhibitörleri |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| US20040180880A1 (en) | 2002-10-03 | 2004-09-16 | Lauffer David J. | Piperazine and piperidine derivatives |
| EP1644003A1 (fr) | 2003-06-04 | 2006-04-12 | Vernalis (Cambridge) Limited | Triazolo ´1,5-a!pyrimidines et leur utilisation en medecine |
| EP1781659B1 (fr) | 2003-07-16 | 2008-11-05 | Janssen Pharmaceutica N.V. | Derives de triazolopyrimidine en tant qu'inhibiteurs de glycogene synthase kinase 3 |
| BRPI0418212A (pt) | 2003-12-29 | 2007-04-27 | Banyu Pharma Co Ltd | composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade |
| AU2005286647A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| BRPI0515500A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados piridazina para inibição de estearoil-coa-desaturase |
| EP1812439B2 (fr) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase |
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| WO2007113136A1 (fr) | 2006-03-30 | 2007-10-11 | Basf Aktiengesellschaft | Utilisation de triazolopyrimidines substituées dans la lutte contre des champignons phytopathogènes |
| JP2007332061A (ja) | 2006-06-14 | 2007-12-27 | Nippon Kayaku Co Ltd | 新規ピラゾロ［１，５−ａ］ピリミジン誘導体及びその用途 |
| US8153803B2 (en) | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
| WO2008048914A1 (fr) | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Composés qui modulent le récepteur cb2 |
| US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP2010065024A (ja) * | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤 |
| WO2012080729A2 (fr) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | Inhibiteurs de caséine kinase 1δ (ck1δ) |
| KR101548443B1 (ko) | 2011-02-23 | 2015-08-28 | 화이자 인코포레이티드 | 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진 |
| WO2013000924A1 (fr) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | Dérivés de 1-aryl-4-méthyl-[1,2,4]triazolo[4,3-a]quinoxaline |
| WO2013042139A1 (fr) | 2011-09-23 | 2013-03-28 | Advinus Therapeutics Limited | Composés amides, compositions et applications de ceux-ci |
| US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| CN104302649B (zh) | 2012-03-09 | 2017-06-23 | 莱西肯医药有限公司 | 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法 |
| CA2936886A1 (fr) | 2014-02-27 | 2015-08-03 | Merck Patent Gmbh | Composes heterocycliques en tant qu'inhibiteurs du canal nav, et leurs utilisations |
| AU2015233654B2 (en) | 2014-03-19 | 2018-12-06 | Boehringer Ingelheim International Gmbh | Heteroaryl Syk inhibitors |
| HUE057317T2 (hu) * | 2014-04-23 | 2022-04-28 | Dart Neuroscience Llc | Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok |
| WO2015162515A1 (fr) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1 |
| CN105566321B (zh) | 2014-10-29 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| TWI530688B (zh) | 2014-11-18 | 2016-04-21 | 彭顯智 | 製備微奈米探針設備及方法 |
| CN105753817A (zh) | 2015-01-01 | 2016-07-13 | 成都贝斯凯瑞生物科技有限公司 | 一类取代氮杂环衍生物及其应用 |
| WO2016145614A1 (fr) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Composés de triazolyl pyrimidinone en tant qu'inhibiteurs de pde2 |
| WO2017000277A1 (fr) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclo-composés de triazole substitués utilisés en tant qu'inhibiteurs de pde2 |
| WO2017000276A1 (fr) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Composés hétérocycliques bicycliques utilisés en tant qu'inhibiteurs de pde2 |
| WO2017066705A1 (fr) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Composés, compositions et méthodes d'utilisation contre des granules de stress |
| ES2765738T3 (es) | 2015-11-02 | 2020-06-10 | Janssen Pharmaceutica Nv | Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo |
| WO2017157882A1 (fr) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Inhibiteurs de la voie de biosynthèse de la sérine |
| CA3038916A1 (fr) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | Composes de [1,2,4]triazolo[1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 |
| AU2017353313C1 (en) | 2016-11-02 | 2022-06-09 | Janssen Pharmaceutica Nv | (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors |
| MX385576B (es) | 2016-11-02 | 2025-03-18 | Janssen Pharmaceutica Nv | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2 |
| US20190359609A1 (en) | 2016-12-16 | 2019-11-28 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
-
2017
- 2017-10-31 AU AU2017353313A patent/AU2017353313C1/en not_active Ceased
- 2017-10-31 CN CN201780067757.4A patent/CN109890824B/zh not_active Expired - Fee Related
- 2017-10-31 WO PCT/EP2017/077918 patent/WO2018083101A1/fr not_active Ceased
- 2017-10-31 EP EP17797113.2A patent/EP3535268B1/fr active Active
- 2017-10-31 MX MX2019005123A patent/MX390505B/es unknown
- 2017-10-31 JP JP2019523012A patent/JP7018944B2/ja not_active Expired - Fee Related
- 2017-10-31 EA EA201991094A patent/EA039847B1/ru unknown
- 2017-10-31 BR BR112019008604A patent/BR112019008604A2/pt not_active IP Right Cessation
- 2017-10-31 MA MA046690A patent/MA46690A/fr unknown
- 2017-10-31 ES ES17797113T patent/ES2912264T3/es active Active
- 2017-10-31 KR KR1020197009775A patent/KR20190067788A/ko not_active Abandoned
- 2017-10-31 US US16/346,745 patent/US11319321B2/en active Active
- 2017-10-31 CA CA3038913A patent/CA3038913A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201991094A1 (ru) | 2019-09-30 |
| US11319321B2 (en) | 2022-05-03 |
| AU2017353313A1 (en) | 2019-04-18 |
| EP3535268B1 (fr) | 2022-02-09 |
| ES2912264T3 (es) | 2022-05-25 |
| AU2017353313B2 (en) | 2021-09-16 |
| BR112019008604A2 (pt) | 2019-07-09 |
| CN109890824A (zh) | 2019-06-14 |
| EA039847B1 (ru) | 2022-03-18 |
| CN109890824B (zh) | 2022-05-24 |
| EP3535268A1 (fr) | 2019-09-11 |
| AU2017353313C1 (en) | 2022-06-09 |
| JP2019532990A (ja) | 2019-11-14 |
| MX390505B (es) | 2025-03-20 |
| CA3038913A1 (fr) | 2018-05-11 |
| US20200055858A1 (en) | 2020-02-20 |
| KR20190067788A (ko) | 2019-06-17 |
| MX2019005123A (es) | 2019-06-20 |
| WO2018083101A1 (fr) | 2018-05-11 |
| JP7018944B2 (ja) | 2022-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53675A (fr) | Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret | |
| MA52987A (fr) | Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak | |
| CL2019000942A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| MA50375A (fr) | Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2 | |
| DK3478682T3 (da) | [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser | |
| EP3328840A4 (fr) | Composés bicycliques triazolo substitués en tant qu'inhibiteurs de pde2 | |
| DK3322706T3 (da) | Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer | |
| LT3555097T (lt) | Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai | |
| DK3418281T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme | |
| SG11201801365YA (en) | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | |
| MA46690A (fr) | Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 | |
| ME03672B (fr) | 1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1 | |
| MA43021A (fr) | Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1 | |
| EP2525659A4 (fr) | Composés pyrazolo[1,5-a]pyrimidines en tant qu'inhibiteurs de mtor | |
| EP3380475A4 (fr) | Dérivés d'octahydropyrrolo [3, 4-c | |
| EP3096762C0 (fr) | Pyrazolo[1,5-a]pyrimidines comme composés antiviraux | |
| EP3508487A4 (fr) | COMPOSÉ DE PYRAZOLO [1,5-a]PYRIMIDINE | |
| EP3319966A4 (fr) | Composés hétérocycliques bicycliques utilisés comme inhibiteurs de pde2 | |
| ZA201701814B (en) | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 | |
| EP3551630A4 (fr) | Dérivés d'imidazo [1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta | |
| IL260536B (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| EP3679042A4 (fr) | Dérivés d'imidazo[1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta | |
| EP3313852A4 (fr) | Composés bicycliques pyrazolo/imidazolo substitués en tant qu'inhibiteurs de pde2 | |
| MA46463A (fr) | Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret |